Literature DB >> 23839042

Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells.

Alessandra Pincini1, Giusy Tornillo, Francesca Orso, Marianna Sciortino, Brigitte Bisaro, Maria Del Pilar Camacho Leal, Antonio Lembo, Maria Felice Brizzi, Emilia Turco, Cristiano De Pittà, Paolo Provero, Enzo Medico, Paola Defilippi, Daniela Taverna, Sara Cabodi.   

Abstract

Understanding transcriptional changes during cancer progression is of crucial importance to develop new and more efficacious diagnostic and therapeutic approaches. It is well known that ErbB2 is overexpressed in about 25% of human invasive breast cancers. We have previously demonstrated that p130Cas overexpression synergizes with ErbB2 in mammary cell transformation and promotes ErbB2-dependent invasion in three-dimensional (3D) cultures of human mammary epithelial cells. Here, by comparing coding and non-coding gene expression profiles, we define the invasive signatures associated with concomitant p130Cas overexpression and ErbB2 activation in 3D cultures of mammary epithelial cells. Specifically, we have found that genes involved in amino acids synthesis (CBS, PHGDH), cell motility, migration (ITPKA, PRDM1), and angiogenesis (HEY1) are upregulated, while genes involved in inflammatory response (SAA1, S100A7) are downregulated. In parallel, we have shown that the expression of specific miRNAs is altered. Among these, miR-200b, miR-222, miR-221, miR-R210, and miR-424 are upregulated, while miR-27a, miR-27b, and miR-23b are downregulated. Overall, this study presents, for the first time, the gene expression changes underlying the invasive behavior following p130Cas overexpression in an ErbB2 transformed mammary cell model.

Entities:  

Keywords:  ErbB2; breast cancer; gene expression; invasion; miRNA; p130Cas

Mesh:

Substances:

Year:  2013        PMID: 23839042      PMCID: PMC3841320          DOI: 10.4161/cc.25415

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  64 in total

1.  Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.

Authors:  Dong Keun Rhee; Su Hyung Park; Yeun Kyu Jang
Journal:  Genomics       Date:  2008-10-09       Impact factor: 5.736

2.  Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.

Authors:  Jason W Locasale; Alexandra R Grassian; Tamar Melman; Costas A Lyssiotis; Katherine R Mattaini; Adam J Bass; Gregory Heffron; Christian M Metallo; Taru Muranen; Hadar Sharfi; Atsuo T Sasaki; Dimitrios Anastasiou; Edouard Mullarky; Natalie I Vokes; Mika Sasaki; Rameen Beroukhim; Gregory Stephanopoulos; Azra H Ligon; Matthew Meyerson; Andrea L Richardson; Lynda Chin; Gerhard Wagner; John M Asara; Joan S Brugge; Lewis C Cantley; Matthew G Vander Heiden
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

3.  Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5.

Authors:  Mathilde Romagnoli; Karine Belguise; Ziyang Yu; Xiaobo Wang; Esther Landesman-Bollag; David C Seldin; Dany Chalbos; Sophie Barillé-Nion; Pascal Jézéquel; Margaret L Seldin; Gail E Sonenshein
Journal:  Cancer Res       Date:  2012-10-10       Impact factor: 12.701

Review 4.  Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer.

Authors:  Elizabeth A Comen
Journal:  Discov Med       Date:  2012-08       Impact factor: 2.970

5.  Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.

Authors:  Jennifer F Raven; Virginie Williams; Shuo Wang; Michel L Tremblay; William J Muller; Joan E Durbin; Antonis E Koromilas
Journal:  Cell Cycle       Date:  2011-03-01       Impact factor: 4.534

Review 6.  Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis.

Authors:  Ming Shi; Dan Liu; Huijun Duan; Beifen Shen; Ning Guo
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

7.  Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression.

Authors:  Hyangsoon Noh; Sungguan Hong; Zheng Dong; Zhixing K Pan; Qing Jing; Shuang Huang
Journal:  Genes Cancer       Date:  2011-02

8.  Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors.

Authors:  Weigang Wang; Sumanta Goswami; Kyle Lapidus; Amber L Wells; Jeffrey B Wyckoff; Erik Sahai; Robert H Singer; Jeffrey E Segall; John S Condeelis
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

9.  Cancer's sweet tooth for serine.

Authors:  Ji Luo
Journal:  Breast Cancer Res       Date:  2011-11-28       Impact factor: 6.466

10.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.

Authors:  Richard Possemato; Kevin M Marks; Yoav D Shaul; Michael E Pacold; Dohoon Kim; Kıvanç Birsoy; Shalini Sethumadhavan; Hin-Koon Woo; Hyun G Jang; Abhishek K Jha; Walter W Chen; Francesca G Barrett; Nicolas Stransky; Zhi-Yang Tsun; Glenn S Cowley; Jordi Barretina; Nada Y Kalaany; Peggy P Hsu; Kathleen Ottina; Albert M Chan; Bingbing Yuan; Levi A Garraway; David E Root; Mari Mino-Kenudson; Elena F Brachtel; Edward M Driggers; David M Sabatini
Journal:  Nature       Date:  2011-08-18       Impact factor: 49.962

View more
  12 in total

Review 1.  Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-expressed and functions as an oncogene in several tumor types.

Authors:  Sabine Windhorst; Kai Song; Adi F Gazdar
Journal:  Biochem Pharmacol       Date:  2017-04-02       Impact factor: 5.858

2.  Prognostic and tumor-immune infiltration cell signatures in tamoxifen-resistant breast cancers.

Authors:  Zhenyu Cao; Ziwei Jin; Liyun Zeng; Hongye He; Qitong Chen; Qiongyan Zou; Dengjie Ouyang; Na Luo; Yulong Zhang; Yunchang Yuan; Wenjun Yi
Journal:  Gland Surg       Date:  2021-09

Review 3.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

4.  miR-221/222 control luminal breast cancer tumor progression by regulating different targets.

Authors:  Patrizia Dentelli; Matteo Traversa; Arturo Rosso; Gabriele Togliatto; Cristina Olgasi; Caterina Marchiò; Paolo Provero; Antonio Lembo; Giulia Bon; Laura Annaratone; Anna Sapino; Rita Falcioni; Maria Felice Brizzi
Journal:  Cell Cycle       Date:  2014-04-15       Impact factor: 4.534

5.  MicroRNA-23b regulates cellular architecture and impairs motogenic and invasive phenotypes during cancer progression.

Authors:  Loredana Pellegrino; Jonathan Krell; Laura Roca-Alonso; Justin Stebbing; Leandro Castellano
Journal:  Bioarchitecture       Date:  2013 Jul-Aug

6.  MicroRNA-27a directly targets KRAS to inhibit cell proliferation in esophageal squamous cell carcinoma.

Authors:  Yuzhi Jiang; Yuting Duan; Haibin Zhou
Journal:  Oncol Lett       Date:  2014-11-11       Impact factor: 2.967

Review 7.  Cas proteins: dodgy scaffolding in breast cancer.

Authors:  Giusy Tornillo; Paola Defilippi; Sara Cabodi
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

8.  p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.

Authors:  Brigitte Bisaro; Marianna Sciortino; Shana Colombo; Maria Pilar Camacho Leal; Andrea Costamagna; Isabella Castellano; Filippo Montemurro; Valentina Rossi; Giorgio Valabrega; Emilia Turco; Paola Defilippi; Sara Cabodi
Journal:  Oncotarget       Date:  2016-01-26

Review 9.  p130Cas/BCAR1 scaffold protein in tissue homeostasis and pathogenesis.

Authors:  Maria del Pilar Camacho Leal; Marianna Sciortino; Giusy Tornillo; Shana Colombo; Paola Defilippi; Sara Cabodi
Journal:  Gene       Date:  2015-02-27       Impact factor: 3.688

10.  Analysis of Host Gene Expression Profile in HIV-1 and HIV-2 Infected T-Cells.

Authors:  Krishnakumar Devadas; Santanu Biswas; Mohan Haleyurgirisetty; Owen Wood; Viswanath Ragupathy; Sherwin Lee; Indira Hewlett
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.